Schrödinger | News, Hiring, Layoffs, Competitors, CEO, Fundraising Insights
Schrödinger is a leading scientific software and biotechnology company that specializes in developing advanced computational tools...
Schrödinger is a leading scientific software and biotechnology company that specializes in developing advanced computational tools for drug discovery and materials science. Founded in 1990 and headquartered in New York, Schrödinger's platform supports biopharmaceutical and industrial research globally, with a commitment to innovation in molecular discovery and design.
Website
Headquarters
New York, New York
Size
501-1000 employees
Industry
Software Development
🛍️ Schrödinger Product and Pricing News →
👔 Schrödinger CEO, Management and Leadership Team →
⚔️ Schrödinger Alternatives and Competitors →
💼 Schrödinger Hiring and Layoffs →
🤖 Schrödinger Developer, Integration and Automation News →
📈 Schrödinger Financials, Fundraising and Valuation News →
🛍️ Schrödinger Product and Pricing News
- Schrödinger has introduced robust prediction of relative binding energies for protein–protein complex mutations using free energy perturbation calculations, replacing the previous focus on OPLS5 polarizability and metal treatment.
- Schrödinger's 2025-1 release introduces a new Kinase Conservation Analysis Interface and augmented AI/ML capabilities for biologics, alongside a Mixed Solvent Molecular Dynamics Interface and ligand unbinding kinetics workflow.
- Schrödinger has introduced new applications including ACTIVE LEARNING APPLICATIONS for machine learning acceleration, BIOLUMINATE for biologics discovery, and a CLOUD COMPUTING ENVIRONMENT for secure simulations, indicating a strategic expansion in digital and cloud-based solutions.
- Schrödinger introduced a next-generation tool, FEP+ Residue Scan, offering a 15x speedup in protein engineering predictions, and announced the discovery of KAI-11101, a preclinical DLK inhibitor for neurodegenerative diseases.
- Schrödinger will participate in the 17th Winter Conference on Medicinal & Bioorganic Chemistry from February 2nd to 6th, 2025, in Steamboat Springs, Colorado, instead of the 29th Biennial ORCS Meeting.
- Schrödinger's recent paper, announced by Principal Scientist Ara M. Abramyan, demonstrates that FEP+ accurately predicts RNA/DNA-targeting ligand affinities using the OPLS4 force field.
- Schrödinger will present their innovations in computational screening for catalyst design at the Organic Reactions Catalysis Society meeting on February 9-13, with a talk by Dr. Pavel Dub on February 12.
- Schrödinger's Executive Director Zhe Nie announced the publication of a paper on a new low-dose DHODH inhibitor for malaria chemoprevention.
👔 Schrödinger CEO, Management and Leadership Team
-
Executive Director
[email protected] -
Executive Director[email protected]
-
President and CEO[email protected]
-
Executive Director[email protected]
-
Executive Director[email protected]
-
Chief Technology Officer and Chief Operating Officer, Software[email protected]
-
Executive Director[email protected]
-
Executive Director[email protected]
-
Executive Director[email protected]
-
Executive Director[email protected]
-
Executive Director[email protected]
-
Executive Director[email protected]
-
Chief Financial Officer
-
Executive Director[email protected]
⚔️ Schrödinger Alternatives and Competitors
- Sentient Science Corporation |
- Merck KGaA |
- ArgusLab |
- Dassault Systèmes |
- InSilicoTrials |
- Chemical Computing Group |
- Optibrium |
- Aqemia |
- Cradle |
- Exscientia |
- Buildertrend Solutions |
- COMSOL |
- Dotmatics |
- Certara |
- Simulations Plus |
- Legend Biotech |
- Nuvalent |
- Ionis Pharmaceuticals |
- Blueprint Medicines |
- Elanco Animal |
- InCrowd |
- DrugPatentWatch |
- Atomwise |
- OpenAI |
- MathWorks |
- Boingo Wireless
💼 Schrödinger Hiring and Layoffs
- Schrödinger added a new role for a Materials Science Account Manager in the United States and a Director of Ventures in New York.
- Schrödinger is currently seeking a Director of Ventures in the United States.
- Christine Maraccini has left Schrödinger as Director, Global Payroll in the United States to join Portland Trail Blazers @ the Rose Quarter as Payroll Manager.
- Schrödinger is currently seeking a Director, GxP Quality Assurance and Compliance in the United States.
- Schrödinger is hiring a Solutions Architect for their Enterprise Informatics team in the Illinois/US-Central region, as announced by Magdalene Romero, Vice President of Strategic Accounts.
- Schrödinger is currently seeking a Senior Cybersecurity Engineer in the United States.
- Schrödinger is hiring a Payroll Manager in Portland, OR, offering a competitive salary and benefits, and has been recognized as one of America's 100 Most Loved Workplaces by Newsweek.
- Schrödinger is currently hiring a Customer Success Manager, Life Science in the United States.
🤖 Schrödinger Developer, Integration and Automation News
- Schrödinger's stock surged 15% as the company integrates AI into its drug discovery platform, supported by partnerships with Novartis and Nvidia, and anticipates clinical data from its first three internal drugs.
- Schrödinger has entered a research collaboration and license agreement with Novartis worth over $2 billion to develop small molecule candidates and signed a three-year software agreement to enhance Novartis' access to Schrödinger's technology.
- Schrödinger's Executive Director Zhe Nie announced a collaboration with Structure Therapeutics in the discovery of ACCG-2671, a lead oral small molecule amylin receptor agonist expected to enter Phase 1 clinical development by the end of 2025.
- On January 28, 2025, Schrödinger adopted the Sapio Platform to improve data management and lab efficiency, enhancing its in silico drug discovery process.
- The Amity Institute of Biotechnology used the Schrödinger platform for their research on phytomolecules-antibiotics combinations against E. coli.
- The Indiana Biosciences Research Institute uses Schrödinger's platform to enhance drug discovery and optimize molecular therapeutics.
- Schrödinger collaborated with scientists from University of Hohenheim, University of Massachusetts Amherst, and EXBERRY® by GNT Group to study phycocyanin as a natural alternative to artificial blue colorants using quantum mechanics and classical simulations.
📈 Schrödinger Financials, Fundraising and Valuation News
- Schrödinger's stock is skyrocketing in 2025 as the market favors smaller companies with a market value between $1 billion and $5 billion.
- As of September 2024, Schrödinger had a cash runway of about 2.3 years with US$389 million in cash and no debt, despite increasing its cash burn by 26% and experiencing a 3% drop in operating revenue over the past year.
People also viewed
- eMolecules |
- Signifyd |
- X-Chem |
- HUMAN |
- Feedzai |
- molecule.one |
- Time Doctor
